Volume 56, Issue 3, Pages 534-543 (September 2009) Tolterodine Treatment Improves Storage Symptoms Suggestive of Overactive Bladder in Men Treated With α-Blockers  Christopher Chapple, Sender Herschorn, Paul Abrams, Franklin Sun, Marina Brodsky, Zhonghong Guan  European Urology  Volume 56, Issue 3, Pages 534-543 (September 2009) DOI: 10.1016/j.eururo.2008.11.026 Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 1 Disposition of subjects assigned to study treatment. ER=extended release. European Urology 2009 56, 534-543DOI: (10.1016/j.eururo.2008.11.026) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 2 Effect of treatment on bladder diary variables, showing least squares mean ± SE change from baseline for number of micturitions and urgency episodes per 24h, with daytime and nocturnal events, and UUI episodes per 24h recorded in bladder diaries. PBO=placebo; TER=tolterodine extended release; UUI=urgency urinary incontinence. *p<0.05. †p<0.01. ‡p≤0.001 for treatment differences based on an analysis of covariance model with terms for country, treatment, and treatment-by-country interaction with the baseline value as a covariate. UUI episodes were present in only 15% of enrolled subjects. European Urology 2009 56, 534-543DOI: (10.1016/j.eururo.2008.11.026) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 3 Effect of treatment on International Prostate Symptom Score, showing least squares mean±SE change from baseline for total index score, storage subscale, voiding subscale, and quality of life (QoL) items. PBO=placebo; TER=tolterodine extended release. *p=0.0370 for treatment difference based on an analysis of covariance model with terms for country, treatment, and treatment-by-country interaction with the baseline value as a covariate. European Urology 2009 56, 534-543DOI: (10.1016/j.eururo.2008.11.026) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 4 Effect of treatment on Overactive Bladder Questionnaire scores, showing least squares mean±SE change from baseline for symptom bother scale, total Health-Related Quality of Life (HRQL) scale, and the coping, concern, sleep, and social interaction domains. PBO=placebo; TER=tolterodine extended release. *p=0.0086. †p=0.0491 for treatment differences based on an analysis of covariance model with terms for country, treatment, and treatment-by-country interaction with the baseline value as a covariate. European Urology 2009 56, 534-543DOI: (10.1016/j.eururo.2008.11.026) Copyright © 2008 European Association of Urology Terms and Conditions